The Netherlands Cancer Institute

This phase 2 trial tests whether three cycles of the immunotherapy drug cemiplimab can cure patients with stage I non-small cell lung cancer who cannot undergo surgery or radiation. Researchers will select patients likely to respond to immunotherapy and treat them with cemiplimab…

This phase II trial is testing whether adding dexamethasone, a steroid, to standard hormone therapy can help people with ER+ HER2- metastatic breast cancer whose disease has progressed on the same hormone therapy. The study will enroll 80 participants and will evaluate how well t…

This phase 2 trial tests whether a combination of two drugs—enfortumab vedotin (Padcev) and pembrolizumab (Keytruda)—can help people with muscle-invasive bladder cancer avoid bladder removal. About 56 participants will receive the drugs first, and those who respond well may get r…

This study tests whether adding the immunotherapy drug pembrolizumab to usual post-surgery treatment can help prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1,000 adul…

This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…